Compare NC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | ASMB |
|---|---|---|
| Founded | 1913 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 440.0M |
| IPO Year | 2006 | 2010 |
| Metric | NC | ASMB |
|---|---|---|
| Price | $51.13 | $27.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 11.1K | ★ 85.7K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $7.76 |
| 52 Week High | $59.42 | $39.71 |
| Indicator | NC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 45.64 |
| Support Level | $44.85 | $27.07 |
| Resistance Level | $50.47 | $30.66 |
| Average True Range (ATR) | 2.84 | 1.36 |
| MACD | -0.68 | -0.09 |
| Stochastic Oscillator | 14.40 | 20.72 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.